TP member assaults doctor for asking him to be cautious while driving

Bengaluru, Jul 23: The Siddi community in Karnataka got its first lawmaker as Governor Vajubhai Vala nominated five persons, including Shantharama Budna Siddi, to the Karnataka Legislative Council on Wednesday.

Shantharama Siddi had been working as a social worker and was a post holder at the Vanavasi Kalyan Prakalpa, a tribal welfare initiative of the Rashtriya Swayamsevak Sangh (RSS).

The Siddis, an ethnic group in India, are said to have descended from the people of the East African region. They are included in the list of Scheduled Tribes (ST) in Karnataka.

Apart from the Shantharama, the inclusion of CP Yogishwar, who had left Congress to join BJP in 2017 but failed to retain his seat in the 2018 Assembly polls, is also considered as a big decision.

Adagur H Vishwanath, another former JDS leader, who had quit his party and joined BJP but failed to retain his seat has also caught the attention of the people.

Further, Governor Vala has nominated Talwar Sabanna and Bharathi Shetty to the Upper House in the state.

Mangaluru, Mar 25: The Indian Council of Medical Research (ICMR) has so far given nod to three private laboratories in Karnataka for testing COVID-19. The ICMR comes under the Department of Health, Government of India

The three labs are KMC Hospital Manipal, Shankar Research Centre's laboratory, and SRL laboratory on Bowring Hospital Road at Shivajinagar, Bengaluru.

Eight private labs from Maharashtra, two from Haryana, three from Tamil Nadu, four from Delhi, and three each from Karnataka and Gujarat have been given permission. 

These labs have over 15,000 collection centres all over the country. Blood samples and throat swabs of coronavirus suspects can be given at these centres.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.